NASDAQ$QTRX
Quanterix Corporation · Q4 2019 earnings
Q4 2019 earnings · · Investor relations
Briefing
Announced financial results with a revenue growth of 46% for the quarter and 51% for the full year.
Quanterix Corporation reported strong Q4 2019 financial results, marking its ninth consecutive quarter of strong performance since going public. The company saw significant growth and technology adoption, particularly with its Simoa technology for measuring novel biomarkers.
- Achieved 46% revenue growth in Q4 2019.
- Experienced 51% revenue growth for the full year 2019.
- Expanded the utility of Simoa technology for measuring biomarkers like neurofilament light chain (Nf-L).
- Acquired UmanDiagnostics to secure the supply of Nf-L antibodies.
Headline financials
Revenue & EPS history
Quanterix · Revenue · Quarterly
$15.9M
Revenue by segment
Quanterix · $20.4M total across 3 segments · Q3 2023
- Product Revenue$19.7M—96.4%
- Grant Revenue$499K—2.4%
- Collaboration and License$237K—1.2%
Forward guidance
Quanterix enters 2020 with a solid lineup of new differentiated instruments, serum-based biomarker assays, specialty pharma services and compelling validation stemming from over 650 Simoa-specific inclusions in publications. These advances, plus adoption momentum in drug development, are increasing the longer-term promise for our technologies in the larger, potentially more attractive, clinical landscape.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2019
-3.6%
Avg return
Earnings day
-5.0%
Avg return
5 days after
-1.1%
Avg return
30 days after
30%
10 / 33 earnings
Positive
+18.1%
Q3 2020
Best reaction
-57.3%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.3% | -15.2% | -0.6% | |
| Q4 2025 | -7.1% | -20.1% | -40.1% | |
| Q3 2025 | -2.0% | +12.1% | +47.5% | |
| Q1 2025 | -19.3% | -16.4% | +8.0% | |
| Q4 2024 | -1.8% | -0.8% | -29.3% | |
| Q3 2024 | -19.0% | -25.3% | -27.1% | |
| Q2 2024 | -13.5% | -11.7% | -5.0% | |
| Q1 2024 | -1.7% | -0.7% | -7.0% | |
| Q4 2023 | -2.8% | +20.1% | +0.3% | |
| Q3 2023 | -1.7% | -10.6% | +1.2% | |
| Q2 2023 | +11.0% | +9.5% | +15.4% | |
| Q1 2023 | +1.9% | -6.8% | +33.5% | |
| Q4 2022 | +5.9% | -1.4% | -1.6% | |
| Q3 2022 | -2.1% | +31.4% | +35.9% | |
| Q2 2022 | -57.3% | -40.1% | -45.8% | |
| Q1 2022 | -16.6% | +1.6% | -6.1% | |
| Q4 2021 | -3.1% | -11.9% | -13.5% | |
| Q3 2021 | +3.1% | -1.5% | -32.6% | |
| Q2 2021 | -5.0% | -6.7% | -6.4% | |
| Q1 2021 | +0.7% | -10.2% | +3.4% | |
| Q4 2020 | -20.8% | -18.5% | -25.7% | |
| Q3 2020 | +18.1% | +6.9% | +11.5% | |
| Q2 2020 | +8.5% | +2.6% | +1.3% | |
| Q1 2020 | +3.8% | -3.5% | -4.1% | |
| Q4 2019 | -7.0% | -20.3% | +7.8% | |
| Q3 2019 | +16.8% | +10.2% | +23.8% | |
| Q2 2019 | -5.4% | -17.5% | -17.3% | |
| Q1 2019 | -4.0% | -8.5% | +28.0% | |
| Q4 2018 | -1.1% | -2.7% | +10.3% | |
| Q3 2018 | -0.1% | -4.6% | +7.0% | |
| Q2 2018 | -1.3% | -0.5% | -0.9% | |
| Q1 2018 | +4.0% | +3.5% | -7.4% | |
| Q4 2017 | -1.2% | -8.6% | -1.7% | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro